BMS 813160

Drug Profile

BMS 813160

Alternative Names: BMS813160

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antihyperglycaemics; Pyrazoles; Triazines
  • Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic nephropathies
  • Phase I/II Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 23 Aug 2017 Phase II development is ongoing for Diabetic nephropathies in USA, Canada, France, Denmark
  • 04 Aug 2017 Phase-I/II clinical trials in Pancreatic cancer and Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease) in USA (unspecified route) (NCT03184870)
  • 19 Jun 2017 Bristol-Myers Squibb plans a phase I/II trial for Colorectal cancer and Pancreatic cancer (Metastatic disease, Combination therapy, Late-stage disease) in USA and Canada (NCT03184870)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top